{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"114.0","upperLimit":"114.0","value":"114.0"},{"groupId":"OG001","lowerLimit":"57.0","upperLimit":"407.0","value":"232.0"},{"comment":"Not estimable due to the low number of events","groupId":"OG002","lowerLimit":"54.0","upperLimit":"54.0","value":"NA"},{"comment":"Not estimable due to the low number of events","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG004","lowerLimit":"47.0","upperLimit":"55.0","value":"55.0"},{"groupId":"OG005","lowerLimit":"15.0","upperLimit":"176.0","value":"48.0"},{"groupId":"OG006","lowerLimit":"50.0","upperLimit":"322.0","value":"186.0"},{"groupId":"OG007","lowerLimit":"15.0","upperLimit":"190.0","value":"110.5"},{"groupId":"OG008","lowerLimit":"36.0","upperLimit":"330.0","value":"225.0"},{"comment":"Not estimable due to the low number of events","groupId":"OG009","lowerLimit":"15.0","upperLimit":"99.0","value":"NA"},{"groupId":"OG010","lowerLimit":"23.0","upperLimit":"49.0","value":"49.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"3"}],"units":"Participants"}],"description":"Time to progressive disease is defined as the time from the date of Cycle 1, Day 1 of treatment to the date of documented assessment of progressive disease, plus one day. Participants without tumor progression were censored at the date of their last clinical response assessment.\n\nMedian time to progression was calculated using the Kaplan-Meier method.","dispersionType":"Full Range","groups":[{"description":"Participants received carfilzomib (CFZ) 1.2 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG000","title":"CFZ 1.2 mg/m²"},{"description":"Participants received carfilzomib 2.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG001","title":"CFZ 2.4 mg/m²"},{"description":"Participants received carfilzomib 4.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG002","title":"CFZ 4.0 mg/m²"},{"description":"Participants received carfilzomib 6.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG003","title":"CFZ 6.0 mg/m²"},{"description":"Participants received carfilzomib 8.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG004","title":"CFZ 8.4 mg/m²"},{"description":"Participants received carfilzomib 11.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG005","title":"CFZ 11.0 mg/m²"},{"description":"Participants received carfilzomib 15.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG006","title":"CFZ 15.0 mg/m²"},{"description":"Participants received carfilzomib 20.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG007","title":"CFZ 20.0 mg/m²"},{"description":"Participants received carfilzomib 27.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"OG008","title":"CFZ 27.0 mg/m²"},{"description":"Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles.","id":"OG009","title":"CFZ 20/27 mg/m²"},{"description":"Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles. Participants also received 20 mg dexamethasone (DEX) administered before each dose of carfilzomib (i.e. 40 mg weekly).","id":"OG010","title":"CFZ 20/27 mg/m² + DEX"}],"paramType":"MEDIAN","populationDescription":"Biologic response-evaluable population","reportingStatus":"POSTED","timeFrame":"From the first dose of study drug until 30 days after the last dose. Median duration of treatment was 6.3 weeks in the dose escalation phase and 6.4 weeks in the dose expansion phase.","title":"Time to Progression","type":"SECONDARY","unitOfMeasure":"days"}